Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Mar Vista US Quality Silas Myers, Brian Massey | “Stryker is a leading medical technology company offering specialized orthopedic implants, surgical equipment, and neurotechnology solutions to healthcare providers. The manager maintains a firm bullish stance, arguing that recent stock underperformance reflects transitory operational hurdles and seasonal procedure pacing rather than a damaged long-term medical franchise. The core investment thesis rests on Stryker's wide moat in hospital operating rooms, driven by surgeon relationships, switching costs, and comprehensive robotic surgical platforms. While temporary manufacturing bottlenecks and a premium starting valuation triggered a sharp multiple contraction, the underlying unit economics remain sound. Hospital capital expenditures and core surgical procedure demands remain healthy, supporting high single-digit top-line gains and operating leverage that should compound free cash flows over time. Catalysts include resolution of peripheral vascular supply chain issues in the fourth quarter, organic revenue acceleration toward 8%+ throughout 2026 and 2027, and robotic adoption. Risks center on prolonged procedure deferrals tied to consumer healthcare deductibles, competitive product gaps in select joint categories, and prolonged European market weakness.” | BULL | Q3 2026 Oct 7, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.